招股书显示，核心医疗是一家致力于提供更全面、更创新、更优质的人工心脏产品的创新医疗器械企 业。公司自成立以来，聚焦急、慢性心衰重大临床需求，依托原始创新与关键核心技术攻关，持续推动 人工心脏领域产品迭代升级。 在首轮问询中，关于植入式、介入式人工心脏临床价值和竞争力，商业化进展以及市场空间等问题遭到 追问。 北京商报讯（记者 丁宁）2月2日晚间，上交所官网显示，深圳核心医疗科技股份有限公司（以下简 称"核心医疗"）科创板IPO已披露首轮审核问询函回复。 ...

证券之星消息，截至2026年2月2日收盘，春立医疗(688236)报收于23.1元，下跌1.7%，换手率1.11%， 成交量3.21万手，成交额7586.53万元。 2月2日的资金流向数据方面，主力资金净流入93.69万元，占总成交额1.23%，游资资金净流入168.14万 元，占总成交额2.22%，散户资金净流出261.83万元，占总成交额3.45%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 春立医疗2025年三季报显示，前三季度公司主营收入7.56亿元，同比上升48.75%；归母净利润1.92亿 元，同比上升213.21%；扣非净利润1.81亿元，同比上升311.07%；其中2025年第三季度，公司单季度主 营收入2.68亿元，同比上升109.51%；单季度归母净利润7706.19万元，同比上升531.12%；单季度扣非 净利润7451.86万元，同比上升439.4%；负债率15.65%，投资收益321.7万元，财务费用-972.34万元，毛 利率67.27%。春立医疗（688236）主营业务：植入性骨科医疗器械的研发、生产与销售。 该股最近90天内共有6家机构给出评级，买入评级6家； ...

Key Points - The report highlights the recent increase in shareholding by major stakeholders in several A-share listed companies, indicating confidence in their long-term value and growth potential [10][12]. - Key companies to focus on include Jintian Copper, Pianzaihuang, and Sanofi Biologics, each demonstrating significant management confidence through share buybacks or increases in shareholding [14][20][26]. Group 1: Jintian Copper - Jintian Copper's controlling shareholder plans to increase holdings by no less than 50 million RMB and no more than 100 million RMB, representing an average of 0.36% of the total market value [11][14]. - The company is a leader in copper and copper alloy materials, with a complete industrial chain and a focus on rare earth permanent magnet materials, serving sectors like new energy vehicles and clean energy [14][16]. - Jintian Copper is also the largest recycler of copper in China, emphasizing its commitment to green and low-carbon development [15][16]. Group 2: Pianzaihuang - Pianzaihuang's controlling shareholder plans to increase holdings by no less than 300 million RMB and no more than 500 million RMB, which is about 0.42% of the total market value [12][20]. - The company specializes in traditional Chinese medicine, with its core product, Pianzaihuang, having a history of nearly 500 years and protected formulation techniques [21][22]. - Pianzaihuang is expanding its product line into liver disease, cold medications, and skincare, while also upgrading its pharmaceutical distribution business [22][23]. Group 3: Sanofi Biologics - The Vice Chairman and General Manager of Sanofi Biologics increased her holdings by 1,017.8 million RMB, representing 0.1% of the total shares [12][26]. - The company focuses on diabetes and chronic disease management, transitioning from single glucose monitoring to a multi-parameter detection system [26]. - Sanofi Biologics has expanded its market presence to 187 countries and regions, developing a comprehensive sales system and innovative healthcare solutions [26].

（文章来源：证券日报） 证券日报网讯 2月2日，四方光电在互动平台回答投资者提问时表示，畅合生物目前暂无针对尼帕病毒 的专用检测方案。但畅合生物基于高效生物气溶胶富集与核酸扩增技术，已成功研发了生物气溶胶快速 检测监测产品及解决方案，可现场进行常见人畜病原的分析与风险预警，从而及时防控潜在传播风险。 ...

（文章来源：证券日报） 证券日报网讯 2月2日，微电生理发布公告称，公司的产品一次性使用心腔内超声成像导管于近日获得 了国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》。 ...

Core Viewpoint - The article discusses a bribery case involving a hospital director in Shaanxi Province, highlighting the issue of kickbacks in the medical supply industry and the need for regulatory oversight to ensure fair competition and protect healthcare funds [3][6]. Group 1: Case Details - Li, the director of a bone surgery department, received a total of 2.7205 million yuan in bribes, primarily from orthopedic supply kickbacks [3][4]. - Li accepted 2.469 million yuan from supplier Jia, who promised a 35% kickback on the total supply amount, leading to the use of Jia's products in surgeries from July 2014 to March 2017 [4][5]. - Li also received 231,600 yuan from supplier Sun, who offered a 30% kickback, with the supply agreement in place from January 2018 to January 2019 [5]. Group 2: Implications and Regulatory Actions - The National Healthcare Security Administration (NHSA) stated that medical bribery distorts prescription rights and disrupts normal medical practices, leading to inflated prices for medical supplies [6]. - The NHSA plans to guide local healthcare authorities in evaluating the credit of dishonest companies and enforcing corrective measures to protect healthcare funds [6]. - In 2023, the NHSA has already exposed four bribery cases, indicating a trend of corruption in the pharmaceutical and medical supply sectors [7].

该股主要指标及行业内排名如下： 证券之星消息，截至2026年2月2日收盘，祥生医疗(688358)报收于34.9元，下跌4.7%，换手率1.6%，成 交量1.79万手，成交额6385.82万元。 2月2日的资金流向数据方面，主力资金净流出823.24万元，占总成交额12.89%，游资资金净流入594.2 万元，占总成交额9.31%，散户资金净流入229.04万元，占总成交额3.59%。 近5日资金流向一览见下表： 祥生医疗2025年三季报显示，前三季度公司主营收入3.43亿元，同比下降5.27%；归母净利润9392.05万 元，同比下降4.56%；扣非净利润8696.66万元，同比下降2.69%；其中2025年第三季度，公司单季度主 营收入1.07亿元，同比下降6.68%；单季度归母净利润2422.41万元，同比上升41.95%；单季度扣非净利 润2314.06万元，同比上升53.63%；负债率11.24%，投资收益301.23万元，财务费用-1652.62万元，毛利 率59.82%。祥生医疗（688358）主营业务：超声医学影像设备的研发、制造和销售,为国内外医疗机 构、科研机构、战略合作伙伴等提供各类超声 ...

Group 1 - The "Xiehe Innovation Port" project was officially launched on February 2, with a cooperation agreement signed between the Chinese Academy of Medical Sciences Peking Union Medical College and the Dongcheng District government [2][3] - The project aims to focus on key areas such as innovative drugs, new vaccines, high-end medical devices, and artificial intelligence in healthcare, creating a benchmark innovation platform that integrates achievement transformation, industry incubation, resource docking, talent cultivation, and professional services [6] - The cooperation agreement includes five core components: provision of physical space and supporting services by Dongcheng District, special support policies, establishment of an integrated platform for technology breakthroughs and achievement transformation, creation of a talent cultivation base, and a governance model ensuring efficient operation [6][7]

Core Viewpoint - The major shareholders of Yirui Biotechnology, including Yirui Venture Capital and its affiliates, have completed a share reduction, selling a total of 10.68 million shares, which represents 2.6366% of the total share capital [1] Share Reduction Details - Yirui Venture Capital reduced its holdings by 3.82 million shares through centralized bidding at an average price of 9.85 yuan per share and 6.23 million shares through block trading at an average price of 8.81 yuan per share [1] - Yidazhi reduced its holdings by 38,400 shares through centralized bidding at an average price of 9.85 yuan per share and 250,000 shares through block trading at an average price of 9.76 yuan per share [1] - Yikaire reduced its holdings by 91,800 shares through centralized bidding at an average price of 9.85 yuan per share and 25,000 shares through block trading at an average price of 9.76 yuan per share [1] Post-Reduction Shareholding Structure - After the reduction, Yirui Venture Capital holds 122 million shares, accounting for 30.1973% of the total shares [1] - Yidazhi holds 18.7196 million shares, accounting for 4.6213% of the total shares [1] - Yikaire holds 22.2354 million shares, accounting for 5.4893% of the total shares [1] - The combined holdings of the three parties amount to 223 million shares, representing 55.1625% of the total shares [1]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has exposed multiple cases of kickbacks in the medical industry, particularly in the fields of pharmaceuticals and medical supplies, highlighting the prevalence of corruption and its impact on healthcare costs and competition [3][4]. Group 1: Case Details - A case involving Li, the director of an orthopedic hospital in Shaanxi, revealed that he illegally accepted a total of 2.7205 million yuan in kickbacks, primarily from orthopedic supplies [1]. - Li received 2.469 million yuan from supplier Jia, who promised a 35% kickback on the total supply amount, leading to the procurement of supplies worth 7.0546 million yuan from July 2014 to March 2017 [1]. - Another supplier, Sun, paid Li 231,600 yuan in kickbacks from January 2018 to January 2019, with a total supply value of 772,200 yuan, despite Li lacking the authority to choose suppliers [2]. Group 2: Implications and Responses - The NHSA stated that medical commercial bribery undermines fair competition and increases healthcare costs, as kickbacks can inflate the prices of medical products by at least one-third [3]. - The NHSA plans to guide local healthcare authorities in evaluating the creditworthiness of involved companies and enforce corrective measures against those that fail to comply [3]. - In 2023, the NHSA has already exposed four kickback cases, indicating a significant issue within the pharmaceutical and medical supply sectors [3].